lamivudine has been researched along with zalcitabine in 271 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 210 (77.49) | 18.2507 |
| 2000's | 41 (15.13) | 29.6817 |
| 2010's | 19 (7.01) | 24.3611 |
| 2020's | 1 (0.37) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S | 1 |
| Bader, JP; Cragg, GM; Newman, DJ; Yang, SS | 1 |
| Anastasi, C; Clayette, P; De Clercq, E; Dereuddre-Bosquet, N; Dormont, D; Gondois-Rey, F; Hantz, O; Hirsch, I; Kraus, JL; Pannecouque, C | 1 |
| Austin, DJ; Cheng, YC; Chung, R; Dutschman, GE; Fu, L; Gullen, EA; Huang, ES; Lee, Y; Li, Y; Yeo, H; Zhu, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Agrawal, B; Johar, M; Kumar, R; Kunimoto, DY; Manning, T; Rai, D; Srivastav, NC | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Balzarini, J; Chen, W; De Clercq, E; Jiang, X; Liu, X; Pannecouque, C; Zhan, P | 1 |
| Amblard, F; Amiralaei, S; Bassit, L; Bobeck, D; Cho, JH; Coats, SJ; Detorio, M; Ehteshami, M; McBrayer, TR; Pradere, U; Schinazi, RF; Tao, S; Whitaker, T; Zhang, HW; Zhou, L | 1 |
| Arumugam, SR; Badri, KR; He, JJ; Visalli, RJ; Zhang, X; Zhao, H; Ziobrowski, H | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Abou-Taleb, N; Amblard, F; Amiralaei, S; Bassit, L; Coats, SJ; Domaoal, RA; Ehteshami, M; Khalil, A; Liu, P; Mahmoud, S; McBrayer, T; Ollinger Russell, O; Sari, O; Schinazi, RF; Schutter, C; Tao, S; Whitaker, T; Zhou, L; Zhou, S | 1 |
| Amblard, F; Bassit, LC; Cho, JH; Coats, SJ; De Schutter, C; Domaoal, RA; Ehteshami, M; Jiang, Y; Kasthuri, M; Lee, S; Lin, BY; McBrayer, T; Mengshetti, S; Ollinger Russell, O; Ovadia, R; Pascual, ML; Pattassery, J; Sari, O; Schinazi, RF; Tao, S; Uher, L; Verma, K; Whitaker, T; Zhang, H; Zhou, L | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Cannon, D; Furman, PA; Lloyd, RM; Mathis, R; McMillan, A; Peck, A; Schinazi, RF; Sommadossi, JP; St Clair, M; Wilson, J | 1 |
| Danner, SA; Donn, KH; Hall, ST; Harker, AJ; Hussey, EK; Jonker, P; Lange, JM; van Leeuwen, R | 1 |
| Boehme, RE; Cameron, JM; Cammack, N; Coates, JA; Marr, CL; Penn, CR; Reid, PJ; Rouse, P | 1 |
| Beach, JW; Cannon, D; Choi, WB; Chu, CK; Jeong, LS; Mathis, R; McMillan, A; Peck, A; Schinazi, RF; Yeola, S | 1 |
| Beach, JW; Chang, CN; Cheng, YC; Chu, CK; Doong, SL; Jeong, LS; Liotta, D; Schinazi, R; Tsai, CH; Zhou, JH | 1 |
| Chang, CN; Cheng, YC; Skalski, V; Zhou, JH | 1 |
| Chu, CK; Schinazi, RF; Sommadossi, JP; Xie, MY | 1 |
| Cameron, JM; Cammack, N; Coates, JA; Jenkinson, HJ; Jowett, AJ; Jowett, MI; Pearson, BA; Penn, CR; Rouse, PL; Viner, KC | 1 |
| Boehme, RE; Cameron, JM; Figueiredo, HT; Gray, NM; Hart, GJ; Orr, DC; Penn, CR | 1 |
| Gao, Q; Li, XG; Parniak, MA; Rooke, R; Soudeyns, H; Tremblay, M; Wainberg, MA; Yao, XJ | 1 |
| Cheng, YC; Doong, SL; Liotta, DC; Schinazi, RF; Tsai, CH | 1 |
| de Man, RA; Heijtink, RA; Honkoop, P; Schalm, SW | 1 |
| Portegies, P | 1 |
| Nelson, H | 1 |
| Bartholomew, M; Dienstag, JL; Perrillo, RP; Rubin, M; Schiff, ER; Vicary, C | 1 |
| Benoit, SL; Eron, JJ; Fallon, MA; Jemsek, J; Kuritzkes, DR; MacArthur, RD; Quinn, JB; Rubin, M; Santana, J | 1 |
| Merigan, TC | 1 |
| Jansen, PL | 1 |
| Tastemain, C | 1 |
| Liu, XY; Severini, A; Tyrrell, DL; Wilson, JS | 1 |
| Boucher, CA; Cameron, JM; Cammack, N; Rouse, P; Schipper, P; Schuurman, R; Wainberg, MA | 1 |
| Mitsuya, H | 1 |
| Cameron, J; Fang, H; Gao, Q; Goldberg, E; Gu, Z; Parniak, MA; Salomon, H; Wainberg, MA | 1 |
| Arts, EJ; Fletcher, RS; Gu, Z; Parniak, MA; Wainberg, MA | 1 |
| Belmonte, A; Gelfand, M; Gu, Z; Nguyen, K; Salomon, H; Wainberg, MA | 1 |
| Daniel, MJ; Donn, KH; Evans, GL; Hall, ST; Harker, AJ; Hussey, EK | 1 |
| Beardsley, T | 2 |
| Christopherson, C; Collis, P; Danner, SA; de Jong, D; Loveday, C; Mulder, J; Nijhuis, M; Schipper, P; Schuurman, R; van Leeuwen, R | 1 |
| Cameron, J; Cammack, N; Cooley, TP; Gu, Z; Hirst, HM; McCaffrey, R; Montaner, JS; Ruedy, J; Salomon, H; Wainberg, MA | 1 |
| Harrigan, PR; Kemp, SD; Larder, BA | 1 |
| Barry, DW; Pennington, KN; Rooney, J; St Clair, MH | 1 |
| Bethell, RC; Cameron, JM; Gray, NM; Marr, CL; Penn, CR | 1 |
| Faust, EA; Gao, Q; Gu, Z; Wainberg, MA | 1 |
| de Man, RA; Heijtink, RA; Niesters, HG; Schalm, SW | 2 |
| Gunnarsson, G; Hammer, SM | 1 |
| Bazmi, HZ; Cannon, DL; Chu, CK; Ilksoy, N; Liotta, DC; Lloyd, RM; McMillan, A; Mellors, JW; Nguyen, MH; Schinazi, RF | 1 |
| Kemp, SD; Larder, BA; Parry, NR; Tisdale, M | 1 |
| Chang, CN; Cheng, YC; Dutschman, G; Skalski, V | 1 |
| Daniel, MJ; Gray, MR; Jenner, WN; Newman, JJ; O'Neill, RM; Sutherland, DR; Wells, GN; Williams, JL; Wring, SA | 1 |
| Boucher, CA; Hill, A; Ingrand, D; Katlama, C; Kitchen, V; McBride, M; McDade, H; Tubiana, R; van Leeuwen, R; Weber, J | 1 |
| Baines, BS; Dawson, MJ; Drake, CS; Hale, RS; Jones, P; Mahmoudian, M; Montgomery, DS; Piercey, JE; Purvis, IJ; Storer, R | 1 |
| Cooley, TP; Hirst, HM; Montaner, JS; Pluda, JM; Quinn, JB; Reinhalter, NE; Ruedy, J; Shay, LE; Vicary, CA; Warthan, SN | 1 |
| Ashman, C; Belmonte, AR; Cammack, N; Hooker, EU; Jin, H; Mansour, TS; Salomon, H; Wainberg, MA; Wang, W | 1 |
| Benhamou, Y; Dohin, E; Gentilini, M; Huraux, JM; Katlama, C; Lunel-Fabiani, F; Opolon, P; Poynard, T | 1 |
| Berthillon, P; Camplo, M; Charvet, AS; Chermann, JC; Faury, P; Graciet, JC; Hantz, O; Mourier, N; Trépo, C; Turin, F | 1 |
| Cupler, EJ; Dalakas, MC | 1 |
| Dudley, MN | 1 |
| Cohen, J | 1 |
| Evans, GL; Harker, AJ; Hawley, AE; Morris, DM | 1 |
| Fong, IW | 1 |
| Morris, DM; Selinger, K | 1 |
| Balzarini, J | 1 |
| Camplo, M; Charvet, AS; Chermann, JC; Faury, P; Graciet, JC; Kraus, JL; Mourier, N | 1 |
| Hsyu, PH; Lloyd, TL | 1 |
| Dionne, G; Gao, Q; Gu, Z; Hiscott, J; Wainberg, MA | 1 |
| Altria, KD; Drake, C; Goodall, DM; Rogan, MM | 1 |
| Liotta, DC; Schinazi, RF; Shewach, DS | 1 |
| Costigliola, P; Degrassi, A; Facchini, A; Lisignoli, G; Monaco, MC; Ricchi, E; Toneguzzi, S | 1 |
| Arts, EJ; Boulerice, F; Geleziunas, R; Goldman, H; Wainberg, MA | 1 |
| Boucher, C; Cameron, J; Cammack, N; Gao, Q; Gu, Z; Parniak, MA; Wainberg, MA | 1 |
| Arts, EJ; Gu, Z; Le Grice, SF; Marois, JP; Wainberg, MA | 1 |
| Brenner, B; Lalonde, R; Mercure, L; Phaneuf, D; Wainberg, MA | 1 |
| Chou, TC; Hirsch, MS; Merrill, DP; Moonis, M | 1 |
| Barbosa, P; Buchbinder, S; Feinberg, M; Harrer, E; Harrer, T; Johnson, RP; Walker, BD | 1 |
| Hostetler, KY; Korba, BA; Liotta, DC; Richman, DD; Schinazi, RF; Voronkov, M; Xie, H | 1 |
| Hui, F; Kavlick, MF; Kojima, E; Mitsuya, H; Pluda, JM; Shirasaka, T; Yarchoan, R | 1 |
| Balis, FM; Blaney, SM; Daniel, MJ; Godwin, K; Harker, AJ | 1 |
| Gataric, N; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Schechter, MT; Yip, B | 1 |
| Staszewski, S | 1 |
| Boucher, CA; Cammack, N; Hill, A; Ingrand, D; Loveday, C; Robert, C; Weber, J | 1 |
| Balzarini, J; Camarasa, MJ; De Clercq, E; Karlsson, A; Pelemans, H; Pérez-Pérez, MJ; San-Félix, A | 1 |
| Boehme, R; Bonhoeffer, S; Hill, AM; McDade, H; Nowak, MA; Thomas, HC | 1 |
| Borkow, G; Castriota, G; Drosopoulos, WC; Gu, Z; Hsu, M; Islam, S; Manne, J; Parniak, M; Prasad, VR; Salomon, H; Song, Q; Wainberg, MA | 1 |
| Eron, JJ; Hussey, EK; Martin, D; Moore, KH; Mydlow, PK; Raasch, RH; Yuen, GJ | 1 |
| Balis, F; Brouwers, P; Church, J; Farley, M; Goldsmith, J; Keller, A; Lewis, LL; Mueller, B; Pizzo, PA; Rubin, M; Shearer, GM; Sloas, M; Venzon, D; Wheeler, S; Wood, L; Yuen, G | 1 |
| Danner, SA; Dellarnonica, P; Harrigan, PR; Hill, AM; Johnson, MA; Loveday, C; McDade, H; Picazo, JJ; Skinhøj, P; Staszewski, S; Verity, L | 1 |
| Clumeck, N; Hill, AM; Ingrand, D; Johnson, M; Katlama, C; Loveday, C; Mallolas, J; McDade, H; Pearce, G; Staszewski, S | 1 |
| Back, NK; Berkhout, B; Boucher, CA; Keulen, W; Nijhuis, M; Oude Essink, BO; van Gennip, AH; van Kuilenburg, AB | 1 |
| Jozwiakowski, MJ; Nguyen, NA; Sisco, JM; Spancake, CW | 1 |
| Bartlett, JA; Benoit, SL; Ehmann, WC; Fallon, MA; Johnson, VA; Quinn, JB; Rubin, M; Self, PL; Sepulveda, GE; Tsoukas, C | 1 |
| Rowe, PM | 1 |
| Grimm, I | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Bloor, S; Harrigan, PR; Kemp, SD; Kinghorn, I; Kohli, A; Larder, BA; Nájera, I | 1 |
| Korba, BE | 1 |
| Andries, K; De Brabander, M; De Crée, J; De Raeymaeker, M; Miller, V; Moeremans, M; Pearce, G; Peeters, M; Rehmet, S; Stark, T; Staszewski, S; Stoffels, P; Van den Broeck, R; Verbiest, W | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Khoo, S; Veal, GJ | 1 |
| Balzarini, J; De Clercq, E; Heijtink, R; Kruining, J; McGuigan, C; Pelemans, H; Wedgwood, O | 1 |
| Boucher, CA; De Boer, RJ | 1 |
| Gerberding, JL | 1 |
| Hsyu, PH; Statkevich, P; Sweeney, KR; Taft, DR | 1 |
| Chikami, GK; Piazza-Hepp, TD; Styrt, BA | 1 |
| Lane, HC; Masur, H; Spooner, KM | 1 |
| Chinitz, MA | 1 |
| Faulds, D; Lea, AP | 1 |
| Carr, A; Cooper, DA; Emery, S; Kelleher, A; Law, M | 1 |
| Balagué, M; Cabrera, C; Clotet, B; De Clercq, E; Martínez-Picado, J; Puig, T; Romeu, J; Ruiz, L; Schmit, JC; Segura, A; Sirera, G; Tural, C; Vandamme, AM | 1 |
| Lloyd, RM; North, TW; Remington, KM; Schinazi, RF; Smith, RA | 1 |
| Aguirrebengoa, K; Mallolas, J; Torres Tortosa, M; Uriz, J | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Back, DJ; Barry, MG; Khoo, SH; Veal, GJ | 1 |
| Heins, JR | 1 |
| Craig, C; Moyle, G | 1 |
| Costello, CE; Nelson, MR; Walsh, JC | 1 |
| Böhler, T; Debatin, KM; Geiss, M; Haas, J; Herr, I | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Kewn, S; Veal, GJ | 1 |
| Aldrich, CE; Averett, D; Condreay, L; Mason, WS; Moraleda, G; Saputelli, J | 1 |
| Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sandres, K; Tamalet, C | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Manion, V | 1 |
| Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S | 1 |
| Conway, B; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Rhone, SA; Schechter, MT; Sherlock, C; Yip, B | 1 |
| DeMasi, R; Hill, AM; Montaner, JS | 1 |
| Burt, MS; Mills, RJ; Scott-Lennox, JA | 1 |
| Stevens, TP; Watson, WJ; Weinberg, GA | 1 |
| Blanchard, G; Blum, L; Calvo, F; Danne, O; Lebbé, C; Morel, P; Pellet, C; Vérola, O | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Bridges, EG; Cheng, YC; Dutschman, DE; Liu, SH; Zhu, YL | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Pineda, JA; Puig, T; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Puig, T; Rossau, R; Ruiz, L; Schmit, JC; Stuyver, L; Van Laethem, K; Vandamme, AM; Vanderlinden, I | 1 |
| Font, E; Lasanta, S; Rodríguez, JF; Rosario, O | 1 |
| Bachmeyer, C; Blum, L | 1 |
| Kempf-Durepaire, G; Krantz, V; Lang, JM; Nicolle, M; Partisani, M; Rey, D; Schmitt, AC; Schmitt, MP | 1 |
| Saag, MS; Schooley, RT | 1 |
| Gitterman, SR; Pratt, RD; Struble, KA | 1 |
| Phillips, L | 1 |
| Cheng, YC; Fu, L; Liu, SH | 1 |
| Anderson, KS; Feng, JY; Schinazi, RF; Shi, J | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arlotto, C; Bernard, A; Bernard-Pomier, G; Breittmayer, JP; Dellamonica, P; Pradier, C; Pugliese, P; Roger, PM | 1 |
| Arrizabalaga, J; Clotet, BG; Cruceta, A; Dalmau, D; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Grau, I; Knobel, H; Miró, JM; O'Brien, WA; Podzamczer, D; Pumarola, T; Romeu, J; Sambeat, MA | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| Klarmann, GJ; North, TW; Preston, BD; Schinazi, RF; Smith, RA | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Puig, T; Rey, C; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Gazzard, BG; Moyle, GJ | 1 |
| Aoki, M; Genka, I; Kikuchi, Y; Oka, S; Tachikawa, N; Teruya, K; Yamaguchi, M; Yamamoto, Y; Yasuoka, A; Yasuoka, C | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Evans, C; Hermans, P; Muyldermans, G; Ruiz, L; Schmit, JC; Schneider, F; Simons, P; Stuyver, L; Van Laethem, K; Van Vaerenbergh, K; Van Wanzeele, F; Van Wijngaerden, E; Vandamme, AM; Verhofstede, C | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Beylot, J; Dabis, F; Dequae-Merchadou, L; Marimoutou, C; Mercié, P; Morlat, P; Neau, D; Pellegrin, I | 1 |
| Boschini, A; Calista, D | 1 |
| Babiker, AG; Clarke, JR; Hooker, MH; Kaye, S; Tedder, R; Weber, JN | 1 |
| Albrecht, MA; Balfour, HH; Hammer, SM; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, MF; Valdez, H | 1 |
| La Seta Catamancio, S; Parker, D; Rusconi, S; Sheridan, F | 1 |
| Arendt, G; Hefter, H; Theisen, A; von Giesen, HJ | 1 |
| Cheng, YC; Chevallier, M; Guerret, S; Hantz, O; Jamard, C; King, I; Le Guerhier, F; Peyrol, S; Pichoud, C; Trépo, C; Zoulim, F | 1 |
| Copeland, WC; Lim, SE | 1 |
| Fischer, KP; Tyrrell, DL; Urban, S | 1 |
| Anderson, KS; Feng, JY; Johnson, AA; Johnson, KA | 1 |
| Mascolini, M | 4 |
| Colvin, R; Haas, G | 1 |
| Gilden, D | 2 |
| Cheng, B | 1 |
| Prescott, LM | 1 |
| James, JS | 6 |
| Poscher, M | 2 |
| Conant, M | 1 |
| Rubin, M | 1 |
| Japour, AJ | 1 |
| Levin, J | 1 |
| Baker, R | 3 |
| Chang, HE | 1 |
| Boucher, CA | 1 |
| Smart, T | 4 |
| Coombs, R; Cotton, D; Hammer, S; Saag, M; van der Horst, C | 1 |
| Alcorn, K | 1 |
| Torres, G | 2 |
| Cooper, EC | 1 |
| Doepel, L; Folkers, G | 1 |
| Cain, D; Clarke, JR; Erlwein, O; Frater, AJ; Grigg, AR; Hill, CL; McClure, MO; Patton, G; Rosenblum, LL | 1 |
| Bacheler, L; Bazmi, H; Diamond, S; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Hammond, J; Klabe, R; Liotta, DC; Manion, DJ; Mellors, J; Otto, MJ; Pierce, M; Rayner, M; Schinazi, RF; Stuyver, L; Trainor, G; Wu, JT; Zhang, H | 1 |
| Brůcková, M; Linka, M; Reinis, M; Stanková, M; Vandasová, J | 1 |
| Anderson, KS | 1 |
| Domingo, E; Mas, A; Menéndez-Arias, L; Vázquez-Alvarez, BM | 1 |
| Choi, Y; Chong, Y; Choo, H; Chu, CK; Mathew, J; Schinazi, RF | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Copeland, WC; Lim, SE; Longley, MJ; Ponamarev, MV | 1 |
| Bacheler, L; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Otto, MJ; Schinazi, RF; Shi, G; Wu, JT; Zhang, H | 1 |
| Derse, D; Hill, SA; Lloyd, PA; McDonald, S; Wykoff, J | 1 |
| Macher, A; Paul, SM; Thomas, D | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J; Sagir, A | 1 |
| de Baar, MP; de Ronde, A; Ruiter, JP; Tebas, P; Timmermans, EC; Wanders, RJ | 1 |
| Abdul, HM; Ansari, MA; Butterfield, DA; Nath, A; Opii, WO; Sultana, R | 1 |
| Grier, JP; Hernandez-Santiago, BI; Mathew, JS; Rapp, KL; Schinazi, RF | 1 |
| Breytenbach, JC; du Plessis, J; Gerber, M | 1 |
| Faetkenheuer, G; Hartmann, P; Jung, N; Knispel, M; Lehmann, C; Rubbert, A; Stellbrink, HJ; Taubert, D; van Lunzen, J | 1 |
| Berrino, L; Scaglione, F | 1 |
| Allweiss, L; Bierwolf, J; Dandri, M; Lütgehetmann, M; Matthes, E; Petersen, J; Pollok, JM; Volz, T; Warlich, M | 1 |
| Ayala, AP; Ellena, J; Guimarães, FF; Honorato, SB; Martins, FT | 1 |
| Achigecheva, PY; Balakhnin, SM; Petrova, AS; Shtil, AA; Silnikov, VN; Stetsenko, DA; Vasilyeva, SV | 1 |
22 review(s) available for lamivudine and zalcitabine
| Article | Year |
|---|---|
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
Topics: Amino Acid Sequence; Anti-HIV Agents; HIV-1; Models, Biological; Models, Chemical; Molecular Sequence Data; National Institutes of Health (U.S.); Retrospective Studies; United States; Virus Replication | 2001 |
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
New nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Arabinofuranosyluracil; Chronic Disease; Drug Evaluation, Preclinical; Famciclovir; Hepatitis B; Humans; Lamivudine; Nucleosides; Zalcitabine | 1995 |
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Topics: Antiviral Agents; Didanosine; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1995 |
Clinical pharmacokinetics of nucleoside antiretroviral agents.
Topics: Animals; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.
Topics: Animals; Antiviral Agents; Dideoxyadenosine; Dideoxynucleosides; Humans; Lamivudine; Purines; Pyrimidines; Retroviridae; Spiro Compounds; Stavudine; Thymidine; Uridine; Zalcitabine; Zidovudine | 1994 |
New developments in antiviral therapy for chronic hepatitis B infection.
Topics: 2-Aminopurine; Antiviral Agents; Arabinofuranosyluracil; Clinical Trials as Topic; Famciclovir; Hepatitis B; Hepatitis, Chronic; Humans; Interferon-alpha; Lamivudine; Treatment Outcome; Zalcitabine | 1995 |
Prophylaxis for occupational exposure to HIV.
Topics: Antiviral Agents; Health Personnel; HIV Infections; Humans; Lamivudine; Occupational Exposure; Protease Inhibitors; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Clinical toxicity of antiretroviral nucleoside analogs.
Topics: Animals; Antiviral Agents; Didanosine; Humans; Lamivudine; Mitochondria; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1996 |
Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Meta-Analysis as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Ritonavir.
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; CD4-Positive T-Lymphocytes; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocyte Count; Randomized Controlled Trials as Topic; Ritonavir; RNA, Messenger; Zalcitabine; Zidovudine | 1996 |
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
The development of resistance of HIV-1 to zalcitabine.
Topics: Amino Acids; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Zalcitabine | 1997 |
[Antiretroviral treatment in human immunodeficiency virus infection].
Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Toxicity of antiretroviral agents.
Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Finding a role for zalcitabine in the HAART era.
Topics: Anti-HIV Agents; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Saquinavir; Zalcitabine; Zidovudine | 1998 |
Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Cytidine Triphosphate; Deoxycytosine Nucleotides; Dideoxynucleotides; DNA Polymerase gamma; DNA-Directed DNA Polymerase; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Nucleosides; Reverse Transcriptase Inhibitors; Stereoisomerism; Zalcitabine | 2002 |
Contraindicated antiretroviral drug combinations.
Topics: Anti-Retroviral Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zalcitabine | 2003 |
[New approaches in the treatment of hepatitis B].
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Emtricitabine; Famciclovir; Guanine; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Organophosphorus Compounds; Polyethylene Glycols; Prodrugs; Prognosis; Recombinant Proteins; Tenofovir; Zalcitabine | 2004 |
43 trial(s) available for lamivudine and zalcitabine
| Article | Year |
|---|---|
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Headache; HIV Infections; Humans; Infusions, Intravenous; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine | 1992 |
A preliminary trial of lamivudine for chronic hepatitis B infection.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Chronic Disease; DNA, Viral; Double-Blind Method; Female; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine | 1995 |
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Interspecies scaling and pharmacokinetic parameters of 3TC in humans.
Topics: Animals; Antiviral Agents; Body Weight; Cross-Over Studies; Dogs; HIV Seropositivity; Humans; Infusions, Intravenous; Lamivudine; Male; Rats; Reverse Transcriptase Inhibitors; Species Specificity; Zalcitabine | 1994 |
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Complex; Base Sequence; DNA Primers; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Female; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Lamivudine; Male; Molecular Sequence Data; Mutation; Phenotype; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Zalcitabine | 1995 |
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Topics: Antiviral Agents; Base Sequence; CD4 Lymphocyte Count; Cell Line; Codon; Drug Resistance, Microbial; Drug Therapy, Combination; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Serial Passage; Zalcitabine; Zidovudine | 1995 |
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Biopterins; CD4 Lymphocyte Count; Disease Progression; Dose-Response Relationship, Drug; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Neopterin; Zalcitabine | 1995 |
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; beta 2-Microglobulin; Female; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Time Factors; Zalcitabine | 1995 |
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Virus Replication; Zalcitabine | 1995 |
Hair loss associated with lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alopecia; Antiviral Agents; Female; Humans; Lamivudine; Male; Middle Aged; Zalcitabine | 1994 |
Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Resistance, Microbial; Genotype; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Zidovudine and lamivudine: results of phase III studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
Topics: Adult; AIDS-Related Complex; Antigen-Antibody Complex; Antiviral Agents; Dose-Response Relationship, Drug; HIV; HIV Core Protein p24; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viremia; Zalcitabine | 1995 |
Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole.
Topics: Administration, Oral; Adult; Analysis of Variance; Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Seropositivity; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine | 1996 |
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Lamivudine; Male; Pancreatitis; Risk Factors; RNA, Viral; Treatment Outcome; Zalcitabine | 1996 |
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biopterins; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Neopterin; Polymerase Chain Reaction; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
Topics: Acetamides; Acetophenones; Adult; Antiviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Cross-Over Studies; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Pilot Projects; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Lymphocyte Count; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Viral Load; Zalcitabine; Zidovudine | 1996 |
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay.
Topics: Adult; Anti-HIV Agents; Colorimetry; Didanosine; DNA, Viral; Evaluation Studies as Topic; Female; HIV-1; Humans; Indinavir; Lamivudine; Male; Polymerase Chain Reaction; Proviruses; Ritonavir; RNA, Viral; Transcription, Genetic; Zalcitabine; Zidovudine | 1998 |
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Quality of Life; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Ritonavir; RNA, Viral; Spain; Stavudine; Viremia; Zalcitabine; Zidovudine | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Multivariate Analysis; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Codon; DNA; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Therapy, Combination; Evaluation Studies as Topic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Nucleosides; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2000 |
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Motor Skills; Stavudine; Zalcitabine; Zidovudine | 2001 |
Final CESARE trial results show continued clinical and survival benefit.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Survival Rate; Zalcitabine; Zidovudine | 1997 |
3TC: expanded access will be limited.
Topics: Antiviral Agents; Humans; Lamivudine; Zalcitabine | 1995 |
3TC expanded access program: new requirement for CD4 less than 100.
Topics: CD4 Lymphocyte Count; HIV Infections; Humans; Lamivudine; Zalcitabine | 1995 |
Merck protease inhibitor trial seeks persons with CD4 count under 50.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Industry; Drug Therapy, Combination; HIV Protease Inhibitors; Hotlines; Humans; Indinavir; Lamivudine; Patient Selection; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1995 |
New protease inhibitor studies.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1995 |
Treatment for primary infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Cohort Studies; Controlled Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Placebos; Pyridines; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Agouron starts phase III protease inhibitor studies.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Lamivudine; Placebos; Zalcitabine; Zidovudine | 1996 |
Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Viral Load; Zalcitabine; Zidovudine | 2002 |
206 other study(ies) available for lamivudine and zalcitabine
| Article | Year |
|---|---|
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine | 2000 |
Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
Topics: Amidines; Anti-HIV Agents; Antiviral Agents; Cell Extracts; Cell Line; Culture Media; Drug Stability; Hepatitis B virus; HIV-1; Humans; Hydrolysis; In Vitro Techniques; Lamivudine; Monocytes; Structure-Activity Relationship | 2004 |
Synthesis and antiviral activity of helioxanthin analogues.
Topics: Antiviral Agents; Benzofurans; Cytomegalovirus; Dioxoles; Hepacivirus; Hepatitis B virus; Herpesvirus 1, Human; Herpesvirus 2, Human; Herpesvirus 4, Human; HIV; Lactones; Lignans; Naphthalenes; Structure-Activity Relationship | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides.
Topics: Adenosine; Alkynes; Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Dideoxynucleosides; Drug Resistance, Bacterial; Guanosine; Microbial Sensitivity Tests; Mycobacterium avium; Mycobacterium bovis; Mycobacterium tuberculosis; Purine Nucleosides; Structure-Activity Relationship; Uridine | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrroles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazines | 2013 |
β-D-2'-C-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms.
Topics: 2-Aminopurine; Amides; Antiviral Agents; Cell Line; Cells, Cultured; Guanosine Triphosphate; Hepacivirus; Hepatitis C; Humans; Methylation; Phosphoric Acids; Prodrugs; Ribonucleosides | 2015 |
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
Topics: Acyclovir; Animals; Antiviral Agents; Betulinic Acid; Chlorocebus aethiops; Herpesvirus 2, Human; HIV Reverse Transcriptase; HIV-1; Humans; Pentacyclic Triterpenes; Triterpenes; Vero Cells; Virus Replication | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
Topics: Antiviral Agents; Cells, Cultured; Dose-Response Relationship, Drug; Genotype; Hep G2 Cells; Hepacivirus; Humans; Microbial Sensitivity Tests; Molecular Structure; Prodrugs; Ribonucleotides; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication | 2017 |
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
Topics: Animals; Antiviral Agents; Cell Line, Tumor; Deoxyribonucleosides; Deoxyuracil Nucleotides; Dogs; Drug Discovery; Enzyme Inhibitors; Hepacivirus; Humans; Male; Microsomes, Liver; Prodrugs; Viral Nonstructural Proteins | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
Topics: Antiviral Agents; Emtricitabine; HIV; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stereoisomerism; Zalcitabine; Zidovudine | 1992 |
Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine.
Topics: Acquired Immunodeficiency Syndrome; Blood Platelets; Cells, Cultured; Humans; Lamivudine; Lymphocytes; Pentosyltransferases; Phosphorylation; Pyrimidine Phosphorylases; Stereoisomerism; Thymidine Phosphorylase; Zalcitabine; Zidovudine | 1992 |
Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes.
Topics: Antiviral Agents; HIV-1; Humans; Lamivudine; Lymphocytes; Microbial Sensitivity Tests; Stereoisomerism; Structure-Activity Relationship; Zalcitabine; Zidovudine | 1992 |
Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication.
Topics: Antiviral Agents; Cell Line; Cytidine Deaminase; DNA Replication; DNA, Mitochondrial; Hepatitis B virus; Humans; Lamivudine; Nucleoside Deaminases; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity; Transfection; Zalcitabine | 1992 |
Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents.
Topics: Antiviral Agents; Base Sequence; Biological Transport; Cells, Cultured; Deoxycytidine Kinase; Hepatitis B; Hepatitis B virus; Humans; In Vitro Techniques; Lamivudine; Mitochondria; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; Oligodeoxyribonucleotides; Phosphorylation; Zalcitabine | 1992 |
Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells.
Topics: Cell Survival; Colony-Forming Units Assay; Dideoxynucleosides; Granulocytes; Hematopoietic Stem Cells; Humans; Lamivudine; Macrophages; Stereoisomerism; Zalcitabine | 1992 |
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
Topics: Cell Death; Cells, Cultured; Didanosine; Giant Cells; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; RNA-Directed DNA Polymerase; Tritium; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma.
Topics: Antiviral Agents; Base Sequence; DNA Polymerase I; DNA Polymerase II; DNA Polymerase III; DNA-Directed DNA Polymerase; HIV; Kinetics; Lamivudine; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; Nucleotides; Peptide Chain Termination, Translational; Polyribonucleotides; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine | 1992 |
Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytosine; Drug Resistance, Microbial; HIV-1; Humans; Lamivudine; Nucleosides; Viral Plaque Assay; Virus Replication; Zalcitabine; Zidovudine | 1991 |
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.
Topics: Antiviral Agents; Blotting, Northern; Carcinoma, Hepatocellular; Cell Survival; DNA, Mitochondrial; Hepatitis B virus; Humans; In Vitro Techniques; Lamivudine; Liver Neoplasms; Mitochondria; Molecular Structure; RNA, Viral; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication; Zalcitabine | 1991 |
Hepatitis B reactivation after lamivudine.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Prednisone; Recurrence; Virus Activation; Zalcitabine | 1995 |
HIV-1, the brain, and combination therapy.
Topics: Adult; AIDS Dementia Complex; Antiviral Agents; Child; Didanosine; Drug Combinations; HIV-1; Humans; Lamivudine; Neuroprotective Agents; Stavudine; Zalcitabine; Zidovudine | 1995 |
FDA advised to license three anti-HIV agents.
Topics: Adult; Antiviral Agents; Child; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine | 1995 |
A quarter-century of antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
[Selective targetting of antiviral agents to the liver].
Topics: Antiviral Agents; Chylomicrons; Drug Carriers; Granulocyte-Macrophage Colony-Stimulating Factor; Hepatitis, Chronic; Humans; Idoxuridine; Lamivudine; Prodrugs; Reverse Transcriptase Inhibitors; Zalcitabine | 1995 |
Confusion reigns over compassionate use of AIDS drug.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; France; Humans; Lamivudine; Zalcitabine | 1995 |
Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.
Topics: Animals; Antiviral Agents; Base Sequence; Ducks; Hepatitis B Virus, Duck; Kinetics; Lamivudine; Molecular Sequence Data; Nucleic Acid Synthesis Inhibitors; Nucleotides; RNA-Directed DNA Polymerase; Viral Core Proteins; Virus Replication; Zalcitabine | 1995 |
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
Topics: Antiviral Agents; Base Sequence; Binding Sites; Codon; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Isoleucine; Lamivudine; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stereoisomerism; Zalcitabine | 1993 |
[AIDS therapy with reverse transcriptase inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1993 |
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Topics: Amino Acid Sequence; Base Sequence; Cloning, Molecular; Codon; Didanosine; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1994 |
The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cloning, Molecular; Didanosine; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Kinetics; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Polynucleotides; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Substrate Specificity; Templates, Genetic; Zalcitabine | 1994 |
Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Fetal Blood; HIV Core Protein p24; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Microbial Sensitivity Tests; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1994 |
Fighting all the time.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
Topics: CD4 Lymphocyte Count; Drug Resistance, Microbial; HIV Core Protein p24; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine | 1995 |
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
Topics: Antiviral Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine | 1995 |
The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma.
Topics: Base Sequence; Deoxycytidine Monophosphate; DNA; DNA Polymerase III; HeLa Cells; HIV Reverse Transcriptase; Humans; Kinetics; Lamivudine; Lymphocytes; Molecular Sequence Data; Phosphorylation; Phytohemagglutinins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stereoisomerism; Zalcitabine | 1995 |
Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC.
Topics: Antiviral Agents; Base Sequence; Cell Fusion; Cell Line; Coculture Techniques; DNA Mutational Analysis; Drug Resistance, Multiple; Genes, pol; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Monocytes; Polymerase Chain Reaction; Recombination, Genetic; T-Lymphocytes; Virus Cultivation; Zalcitabine; Zidovudine | 1995 |
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
Topics: Antiviral Agents; Base Sequence; Cell Line; Cloning, Molecular; Dideoxynucleosides; Drug Resistance, Microbial; Emtricitabine; Gene Amplification; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Molecular Sequence Data; Moloney murine leukemia virus; Monocytes; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine | 1993 |
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Topics: Amino Acid Sequence; Antiviral Agents; Cell Line; Conserved Sequence; Deoxycytidine; Drug Resistance, Microbial; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Structure-Activity Relationship; T-Lymphocytes; Thionucleosides; Zalcitabine; Zidovudine | 1993 |
The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2',3'-dideoxy-3'-thiacytidine.
Topics: Antiviral Agents; Base Sequence; Exonucleases; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Lamivudine; Molecular Sequence Data; Oligoribonucleotides; Phosphorylation; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Zalcitabine | 1993 |
The production and evaluation of a radioligand and antiserum for the radioimmunoassay of subnanogram per millilitre concentrations of lamivudine.
Topics: Animals; Cross Reactions; Immune Sera; Lamivudine; Ligands; Mass Spectrometry; Nucleotides; Radioimmunoassay; Sensitivity and Specificity; Sheep; Zalcitabine | 1994 |
Enzymatic production of optically pure (2'R-cis)-2'-deoxy-3'-thiacytidine (3TC, lamivudine): a potent anti-HIV agent.
Topics: Antiviral Agents; Biotechnology; Cytidine Deaminase; Enzymes, Immobilized; Escherichia coli; Genes, Bacterial; Lamivudine; Stereoisomerism; Zalcitabine | 1993 |
Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro.
Topics: Animals; Antiviral Agents; Deoxycytidine; Hepatitis B virus; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Liver Neoplasms, Experimental; Stereoisomerism; Thionucleosides; Zalcitabine | 1995 |
Synthesis and antiviral activity of new carbonylphosphonate 2',3'-dideoxy-3'-thiacytidine conjugates.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cytopathogenic Effect, Viral; Drug Evaluation, Preclinical; Ducks; Foscarnet; Giant Cells; Hepatitis B Virus, Duck; HIV-1; Humans; Lamivudine; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Structure-Activity Relationship; Thionucleosides; Zalcitabine | 1994 |
Exacerbation of peripheral neuropathy by lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Humans; Lamivudine; Male; Peripheral Nervous System Diseases; Zalcitabine | 1995 |
AIDS mood upbeat--for a change.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; Gene Products, nef; Herpesviridae; HIV; Humans; Lamivudine; nef Gene Products, Human Immunodeficiency Virus; Sarcoma, Kaposi; Simian Immunodeficiency Virus; Virus Replication; Zalcitabine; Zidovudine | 1995 |
High-performance liquid chromatographic assay for 2'-deoxy-3'-thiacytidine in human serum.
Topics: Antiviral Agents; Autoanalysis; Chromatography, High Pressure Liquid; Dideoxynucleosides; HIV Seropositivity; Hot Temperature; Humans; Lamivudine; Quality Control; Sensitivity and Specificity; Zalcitabine | 1994 |
Determination of 2'-deoxy-3'-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching.
Topics: Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Reproducibility of Results; Zalcitabine | 1994 |
Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates.
Topics: Antiviral Agents; Foscarnet; HIV-1; Lamivudine; Phosphonoacetic Acid; Prodrugs; Structure-Activity Relationship; Virus Replication; Zalcitabine | 1994 |
Automated high-performance liquid chromatographic analysis of (-)-2'-deoxy-3'-thiacytidine in biological fluids using the automated sequential trace enrichment of dialysate systems.
Topics: Animals; Antiviral Agents; Autoanalysis; Body Fluids; Chromatography, High Pressure Liquid; Dialysis; Humans; Kidney; Lamivudine; Rats; Sensitivity and Specificity; Zalcitabine | 1994 |
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine | 1993 |
Enantioselective enzymatic biotransformation of 2'-deoxy-3'-thiacytidine (BCH 189) monitored by capillary electrophoresis.
Topics: Antiviral Agents; beta-Cyclodextrins; Biotransformation; Chromatography, High Pressure Liquid; Cyclodextrins; Cytidine Deaminase; Electrophoresis; Evaluation Studies as Topic; Lamivudine; Stereoisomerism; Zalcitabine | 1993 |
Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase.
Topics: Adenosine Triphosphate; Antiviral Agents; Cytidine Deaminase; Deoxycytidine Kinase; Humans; Kinetics; Lamivudine; Stereoisomerism; Uridine Triphosphate; Zalcitabine | 1993 |
In vitro immunotoxicity of +/- 2'-deoxy-3'-thiacytidine, a new anti-HIV agent.
Topics: Antiviral Agents; B-Lymphocytes; CD3 Complex; Cytokines; Female; HIV Infections; HIV-1; Humans; Immunoglobulins; Lamivudine; Lymphocyte Activation; Male; Phytohemagglutinins; T-Lymphocytes; Zalcitabine; Zidovudine | 1993 |
Effect of 3'-azido-3'-deoxythymidine on human immunodeficiency virus type 1 replication in human fetal brain macrophages.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Brain; Cells, Cultured; DNA, Viral; Fetus; HIV Core Protein p24; HIV-1; Humans; Lamivudine; Macrophages; RNA, Messenger; Stereoisomerism; Time Factors; Virus Replication; Zalcitabine; Zidovudine | 1993 |
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.
Topics: Antiviral Agents; Base Sequence; Cloning, Molecular; Didanosine; Drug Resistance, Microbial; HIV-1; Humans; Lamivudine; Methionine; Mutagenesis, Site-Directed; Mutation; Stereoisomerism; Valine; Zalcitabine | 1993 |
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
Topics: Antiviral Agents; Base Sequence; Cells, Cultured; Didanosine; Dideoxynucleotides; DNA, Viral; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Nucleic Acid Conformation; Nucleosides; Nucleotides; Phytohemagglutinins; RNA, Viral; Thymine Nucleotides; Transcription, Genetic; Zalcitabine; Zidovudine | 1996 |
Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.
Topics: Antiviral Agents; CD8-Positive T-Lymphocytes; Cell Division; Didanosine; Humans; Interleukin-2; Lamivudine; Lymphocyte Activation; Zalcitabine; Zidovudine | 1994 |
Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
Topics: Antiviral Agents; Drug Combinations; Drug Synergism; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Virus Replication; Zalcitabine | 1996 |
Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Conserved Sequence; Deoxycytidine; Didanosine; DNA Primers; Drug Resistance, Microbial; Epitopes; HIV Infections; HIV Reverse Transcriptase; HIV-1; HLA-A2 Antigen; Humans; Lamivudine; Molecular Sequence Data; Oligopeptides; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; T-Lymphocytes, Cytotoxic; Zalcitabine | 1996 |
A new HIV/AIDS drug.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Zalcitabine; Zidovudine | 1996 |
Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells.
Topics: Antiviral Agents; Cell Line; Hepatitis B virus; HIV-1; Humans; Lamivudine; Molecular Structure; Prodrugs; Reverse Transcriptase Inhibitors; Zalcitabine | 1995 |
Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates.
Topics: Animals; Antiviral Agents; Half-Life; Injections, Intravenous; Lamivudine; Macaca mulatta; Male; Stereoisomerism; Zalcitabine | 1995 |
Increased zidovudine prescribing associated with lamivudine availability.
Topics: Antiviral Agents; British Columbia; Drug Utilization; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
New drugs for HIV infection.
Topics: Antiviral Agents; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Zalcitabine | 1996 |
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Topics: Base Sequence; Cells, Cultured; DNA Primers; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Virus Replication; Zalcitabine | 1996 |
Lamivudine as adjunct therapy in HIV.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Viral dynamics in hepatitis B virus infection.
Topics: Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Kinetics; Lamivudine; Models, Biological; Regression Analysis; Reverse Transcriptase Inhibitors; Time Factors; Viremia; Virus Replication; Zalcitabine | 1996 |
Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
Topics: Antiviral Agents; Base Composition; Base Sequence; Deoxyribonucleotides; Drug Resistance, Microbial; HIV Antibodies; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Isoquinolines; Lamivudine; Molecular Sequence Data; Mutation; Neutralization Tests; Quinolines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Saquinavir; Virus Replication; Zalcitabine | 1996 |
New nucleoside analogue, lamivudine, released for HIV therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Topics: Antiviral Agents; Blotting, Western; Cell Cycle; Cell Line; Deoxyribonucleosides; DNA Replication; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Magnesium Chloride; Plasmids; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine | 1996 |
Solubility behavior of lamivudine crystal forms in recrystallization solvents.
Topics: Antiviral Agents; Crystallization; Lamivudine; Microscopy, Electron, Scanning; Temperature; Zalcitabine | 1996 |
New guidelines set for occupational HIV exposure.
Topics: Accidents, Occupational; Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Practice Guidelines as Topic; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Lamivudine: a magic bullet for chronic hepatitis B?
Topics: Antiviral Agents; Chronic Disease; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Zalcitabine | 1996 |
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
Topics: Antiviral Agents; Biopsy; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lymph Nodes; RNA, Viral; Viremia; Zalcitabine; Zidovudine | 1996 |
HIV's Achilles' heel. Drugs and education are starting to slow the AIDS virus.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; Health Education; Humans; Indinavir; Lamivudine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.
Topics: Antiviral Agents; Codon; Drug Therapy, Combination; Genetic Variation; HeLa Cells; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1996 |
In vitro evaluation of combination therapies against hepatitis B virus replication.
Topics: Acyclovir; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepatoblastoma; Humans; Interferon-alpha; Lamivudine; Tumor Cells, Cultured; Virus Replication; Zalcitabine | 1996 |
Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation.
Topics: Antiviral Agents; Humans; Lamivudine; Phosphorylation; Zalcitabine; Zidovudine | 1996 |
Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.
Topics: Antiviral Agents; Base Sequence; Cell Line; DNA Primers; Drug Resistance, Microbial; Hepatitis B virus; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine | 1996 |
Anti-CD4 therapy for AIDS suggested by mathematical models.
Topics: Acquired Immunodeficiency Syndrome; Antigens, CD; Antiviral Agents; CD4 Antigens; CD4 Lymphocyte Count; HIV-1; Host-Parasite Interactions; Humans; Lamivudine; Models, Theoretical; Zalcitabine | 1996 |
Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney.
Topics: Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Interactions; Kidney; Lamivudine; Male; Rats; Rats, Sprague-Dawley; Zalcitabine | 1995 |
Ribavirin for chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Hepatitis C; Humans; Lamivudine; Ribavirin; Zalcitabine | 1996 |
[HIV: to administer protease inhibitors early].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Time Factors; Zalcitabine; Zidovudine | 1996 |
A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
Topics: Animals; Antiviral Agents; Binding Sites; Cats; Cell Line; Drug Resistance, Microbial; Emtricitabine; Immunodeficiency Virus, Feline; Lamivudine; Methionine; Mutagenesis, Site-Directed; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; Threonine; Viral Plaque Assay; Zalcitabine | 1997 |
In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy.
Topics: Anti-HIV Agents; Biotransformation; Drug Evaluation, Preclinical; Drug Interactions; Humans; Lamivudine; Phosphorylation; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1997 |
Treatment options for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Drug Approval; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lamivudine; Male; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Response of HIV-associated thrombocytopenia to triple agent antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Saquinavir; Thrombocytopenia; Zalcitabine; Zidovudine | 1997 |
Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lamivudine; Membrane Glycoproteins; Reverse Transcriptase Inhibitors; RNA, Messenger; T-Lymphocytes; Time Factors; Transcription, Genetic; Zalcitabine; Zidovudine | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Lamivudine (3TC) phosphorylation and drug interactions in vitro.
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Interactions; Humans; Kinetics; Lamivudine; Lymphocyte Activation; Lymphocytes; Mitogens; Models, Chemical; Monocytes; Phosphorylation; Stavudine; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1997 |
Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus.
Topics: Animals; Antiviral Agents; Cells, Cultured; DNA, Circular; DNA, Viral; Emtricitabine; Hepatitis B Virus, Woodchuck; Lamivudine; Liver; Marmota; Rats; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
Topics: Anti-HIV Agents; Cell Count; Cell Survival; Didanosine; Drug Interactions; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Nucleosides; Phosphorylation; Protease Inhibitors; Ritonavir; Saquinavir; Stavudine; Trypan Blue; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1998 |
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine | 1998 |
Profound anemia in a newborn infant of a mother receiving antiretroviral therapy.
Topics: Adult; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Leukocyte Count; Male; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zalcitabine; Zidovudine | 1998 |
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; Herpesvirus 8, Human; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sarcoma, Kaposi; Stavudine; Treatment Outcome; Viral Load; Viremia; Zalcitabine; Zidovudine | 1998 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.
Topics: Antiviral Agents; Biological Products; Deoxycytidine; Deoxycytidine Kinase; DNA-Directed DNA Polymerase; Dose-Response Relationship, Drug; Hepatitis B virus; Humans; Lamivudine; Phosphorylation; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured; Zalcitabine | 1998 |
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zalcitabine; Zidovudine | 1998 |
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Topics: Anti-HIV Agents; Codon; Didanosine; DNA Probes; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 1998 |
Analysis of antiretroviral nucleosides by electrospray ionization mass spectrometry and collision induced dissociation.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Gas Chromatography-Mass Spectrometry; Lamivudine; Models, Chemical; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Secondary Ion; Zalcitabine; Zidovudine | 1998 |
[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
PHS recommends preventive drugs for HIV exposures.
Topics: Antiviral Agents; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Pyridines; United States; United States Public Health Service; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Topics: Acyclovir; Adenine; Antiviral Agents; Arabinofuranosyluracil; DNA-Directed DNA Polymerase; Drug Resistance, Microbial; Drug Resistance, Multiple; Guanine; Hepatitis B virus; Lamivudine; Microbial Sensitivity Tests; Mutation; Nucleic Acid Synthesis Inhibitors; Organophosphonates; Zalcitabine | 1999 |
Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP.
Topics: Base Sequence; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Lamivudine; Molecular Sequence Data; Oligodeoxyribonucleotides; Reverse Transcriptase Inhibitors; Substrate Specificity; Virus Replication; Zalcitabine | 1999 |
Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site.
Topics: Catalytic Domain; Cytidine Triphosphate; Dideoxynucleotides; Dose-Response Relationship, Drug; Drug Resistance; HIV Reverse Transcriptase; HIV-1; Lamivudine; Mutation; Proline; Reverse Transcriptase Inhibitors; Thionucleosides; Thiophenes; Thymine Nucleotides; Transcription, Genetic; Zalcitabine; Zidovudine | 2000 |
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance; Genes, pol; Genotype; HIV-1; Humans; Lamivudine; Point Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1999 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cysteine; Drug Combinations; Drug Therapy, Combination; Glycine; Glycyrrhetinic Acid; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2000 |
Cutaneous side effects induced by indinavir.
Topics: Adult; Alopecia; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Middle Aged; Pruritus; Pyoderma Gangrenosum; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Scalp Dermatoses; Skin; Stavudine; Zalcitabine; Zidovudine | 2000 |
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nucleic Acid Hybridization; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2000 |
Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Topics: Animals; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Circular; DNA, Viral; Drug Administration Schedule; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Lamivudine; Liver; Marmota; Skin Pigmentation; Viremia; Virus Replication; Zalcitabine | 2001 |
Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma.
Topics: Anti-HIV Agents; Cytidine Triphosphate; Deoxyguanine Nucleotides; Deoxyribonucleotides; Dideoxynucleotides; DNA; DNA Polymerase gamma; DNA Replication; DNA-Directed DNA Polymerase; Exodeoxyribonucleases; Humans; Kinetics; Lamivudine; Nucleic Acid Synthesis Inhibitors; Reverse Transcriptase Inhibitors; Stavudine; Substrate Specificity; Thymine Nucleotides; Zalcitabine; Zidovudine | 2001 |
Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism.
Topics: Animals; Antiviral Agents; Catalysis; Diphosphates; DNA Replication; DNA, Viral; Ducks; Genome, Viral; Hepatitis B Virus, Duck; Hydrolysis; Kinetics; Lamivudine; Liver; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virion; Zalcitabine | 2001 |
Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cytidine Triphosphate; Deoxycytosine Nucleotides; Dideoxynucleotides; DNA; DNA Polymerase gamma; DNA Replication; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Exodeoxyribonucleases; Humans; Kinetics; Lamivudine; Mitochondria; Nucleic Acid Synthesis Inhibitors; Reverse Transcriptase Inhibitors; Zalcitabine | 2001 |
AZT studies reinforce benefits of combination.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Lymphocyte Count; Zalcitabine; Zidovudine | 1995 |
Combination 3TC/AZT therapy shows promise.
Topics: CD4 Lymphocyte Count; Codon; Drug Resistance; Drug Therapy, Combination; Drug Tolerance; HIV Infections; Humans; Lamivudine; Mutation; Zalcitabine; Zidovudine | 1995 |
Clinical progress and transmission perils stressed at second human retroviruses conference.
Topics: Acyclovir; AIDS Vaccines; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Herpesviridae; HIV Infections; Humans; Interleukin-2; Lamivudine; Lymphoma, Non-Hodgkin; Retroviridae; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1995 |
AIDS task force grapples with faster access to protease drugs.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Drug Approval; Drug Design; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Treatment Outcome; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
3TC and protease inhibitors: citizen's petition asks faster approval.
Topics: Drug Approval; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; United States; United States Food and Drug Administration; Zalcitabine | 1995 |
AZT + 3TC: early results promising.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Treatment briefs.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Industry; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Nerve Growth Factors; Nervous System Diseases; Pyridines; Recombinant Proteins; Stavudine; Zalcitabine; Zidovudine | 1995 |
3TC rules change again.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Health Care Rationing; Health Priorities; HIV Infections; Humans; Lamivudine; Pharmaceutical Services; United States; Zalcitabine | 1995 |
3TC: the good news and the bad news.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Europe; HIV Infections; Humans; Lamivudine; United States; Zalcitabine; Zidovudine | 1995 |
What we know about anti-HIV drugs.
Topics: Antiviral Agents; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1995 |
3TC expanded access update.
Topics: Antiviral Agents; HIV Infections; Humans; Lamivudine; Zalcitabine | 1995 |
Lamivudine useful against hepatitis B-HIV co-infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Combination antiretroviral treatment: new views, evolving practices.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cells, Cultured; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Approval; Drug Combinations; Drug Therapy, Combination; Health Services Accessibility; Humans; Insurance, Health; Lamivudine; Managed Care Programs; United States; Zalcitabine; Zidovudine | 1995 |
New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Peripheral Nervous System Diseases; Protease Inhibitors; Quinolines; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1995 |
3TC: now available again up to CD4 of 300.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Drug Industry; Drug Therapy, Combination; Humans; Lamivudine; Patient Selection; United States; Zalcitabine; Zidovudine | 1995 |
A closer look at 3TC. Interview by Mark Mascolini.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Antiretroviral drug resistance.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Viremia; Zalcitabine; Zidovudine | 1995 |
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Indinavir; Interleukin-2; Lamivudine; Mutation; Pyridines; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
3TC and saquinavir: we need them now.
Topics: Antiviral Agents; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Glaxo broadens access to 3TC.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Zalcitabine | 1995 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine | 1995 |
Roaches of inner space.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Lamivudine; Mutation; T-Lymphocytes, Cytotoxic; Virulence; Virus Replication; Zalcitabine; Zidovudine | 1995 |
An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
FDA triple header. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Mutation; Quinolines; Salvage Therapy; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
3TC/AZT: just another combination.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
FDA approves 3TC and saquinavir. Food and Drug Administration.
Topics: Antiviral Agents; Drug Approval; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine | 1995 |
Combination therapy increases survival.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
FDA antiviral advisory hearings on lamivudine (Epivir, 3TC), saquinavir (Invirase), stavudine (Zerit, d4T), November 6-8. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Resistance, Microbial; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine | 1995 |
Lamivudine (3TC) approved for combination use with AZT.
Topics: Adult; Antiviral Agents; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Didanosine; Drug Therapy, Combination; HIV; Humans; Lamivudine; Practice Patterns, Physicians'; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
3TC approved: now for the tough questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Zalcitabine; Zidovudine | 1995 |
Merck protease inhibitor: more news from Retroviruses Conference.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Potent new AIDS drugs underscore promise of combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Approval; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Clinicians experiment with post-exposure drug pairs.
Topics: Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Needlestick Injuries; Occupational Exposure; Zalcitabine; Zidovudine | 1996 |
Protease inhibitors shine in triple combinations.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1996 |
Europe out of step with the US.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Costs; Europe; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Ritonavir; Saquinavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
Back to the nukes.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
A surprisingly potent nucleoside analogue.
Topics: Adult; Antiviral Agents; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
AZT and 3TC.
Topics: CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
CDC takes aggressive stance on postexposure prophylaxis. Centers for Disease Control and Prevention.
Topics: Antiviral Agents; Blood-Borne Pathogens; Centers for Disease Control and Prevention, U.S.; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Exposure; Pyridines; Risk Factors; United States; Zalcitabine; Zidovudine | 1996 |
3TC: Glaxo Wellcome broadens patient assistance.
Topics: Antiviral Agents; Drug Industry; Financing, Organized; HIV Infections; Humans; Lamivudine; Zalcitabine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Top AIDS researchers' strategy for antiretroviral treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Patient Compliance; Practice Guidelines as Topic; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1996 |
3TC: combination trial stopped early as clinical benefit shown.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine | 1996 |
3TC treatment may slow HIV mutations, development of drug resistance.
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Lamivudine; Mutation; Zalcitabine | 1996 |
Eradication of HIV: the cutting edge of clinical trial design.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Decision Making; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Zalcitabine; Zidovudine | 1996 |
ddI and d4T plus protease inhibitors.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Differential susceptibility of retroviruses to nucleoside analogues.
Topics: Animals; Antiviral Agents; Cell Line; Cricetinae; Didanosine; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Lamivudine; Mink; Nucleosides; Retroviridae; Reverse Transcriptase Inhibitors; Stavudine; Substrate Specificity; Zalcitabine; Zidovudine | 2001 |
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Topics: Animals; Anti-HIV Agents; Cytidine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Macaca mulatta; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2002 |
Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Topics: Base Sequence; Codon; Czech Republic; Didanosine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Probe Techniques; Molecular Sequence Data; Mutation; Phylogeny; Prevalence; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 2001 |
Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors.
Topics: Amino Acid Sequence; Deoxycytidine Monophosphate; Diphosphates; DNA; DNA Primers; DNA Replication; Drug Resistance, Multiple, Viral; HIV Reverse Transcriptase; Humans; Lamivudine; Molecular Sequence Data; Recombinant Proteins; Reverse Transcriptase Inhibitors; Sequence Alignment; Thymidine Monophosphate; Zalcitabine; Zidovudine | 2002 |
Stereoselective synthesis and antiviral activity of D-2',3'-didehydro-2',3'-dideoxy-2'-fluoro-4'-thionucleosides.
Topics: Animals; Anti-HIV Agents; Antiviral Agents; Binding Sites; Cell Line; Chlorocebus aethiops; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Models, Molecular; Mutation; Purine Nucleosides; Pyrimidine Nucleosides; Quantum Theory; Stereoisomerism; Zalcitabine | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs.
Topics: Amino Acid Sequence; Anti-HIV Agents; Baculoviridae; Binding Sites; DNA Polymerase gamma; DNA Primers; DNA-Directed DNA Polymerase; DNA, Viral; Electrophoretic Mobility Shift Assay; Humans; Lamivudine; Mitochondria; Molecular Sequence Data; Mutagenesis, Site-Directed; Polymerase Chain Reaction; Protein Conformation; Protein Folding; Recombinant Fusion Proteins; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid; Stavudine; Zalcitabine; Zidovudine | 2003 |
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Topics: Adenine; Anti-HIV Agents; Cell Line; Cytidine Triphosphate; Didanosine; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Transfection; Zalcitabine; Zidovudine | 2003 |
Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Cell Line; Dideoxynucleosides; Human T-lymphotropic virus 1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Virus Replication; Zalcitabine; Zidovudine | 2003 |
Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy.
Topics: Anti-HIV Agents; Base Sequence; Blood Platelets; Cell Nucleus; Cells, Cultured; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Feasibility Studies; Fibroblasts; HIV Infections; Humans; Indinavir; Lactic Acid; Lamivudine; Leukocytes, Mononuclear; Nucleic Acid Amplification Techniques; Pyruvic Acid; Stavudine; Zalcitabine | 2006 |
Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia.
Topics: AIDS Dementia Complex; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Bridged-Ring Compounds; Caspase 3; Cerebral Cortex; Cytochromes c; Disease Progression; Gerbillinae; Humans; Lamivudine; Male; Mitochondria; Nerve Tissue Proteins; Neuroprotective Agents; Norbornanes; Oxidation-Reduction; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Inhibitors; Synaptosomes; Thiocarbamates; Thiones; Tyrosine; Zalcitabine | 2007 |
Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cells, Cultured; Drug Interactions; Drug Synergism; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Zalcitabine | 2007 |
Transdermal penetration of zalcitabine, lamivudine and synthesised N-acyl lamivudine esters.
Topics: Administration, Cutaneous; Emulsions; Esters; Female; Humans; In Vitro Techniques; Lamivudine; Microscopy, Confocal; Reverse Transcriptase Inhibitors; Skin; Skin Absorption; Solubility; Zalcitabine | 2008 |
Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.
Topics: Cell Line; Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Lymph Nodes; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Zalcitabine | 2008 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activities.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Treatment Outcome; Zalcitabine | 2012 |
Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.
Topics: Animals; Antiviral Agents; Chimera; Cytidine; DNA, Viral; Hepatitis B; Humans; Lamivudine; Mice; Mice, SCID; Molecular Structure; Urokinase-Type Plasminogen Activator; Viremia; Zalcitabine | 2012 |
Vibrational and thermal analyses of multicomponent crystal forms of the anti-HIV drugs lamivudine and zalcitabine.
Topics: Anti-HIV Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Crystallization; Crystallography, X-Ray; Hot Temperature; Hydrogen Bonding; Lamivudine; Maleates; Molecular Structure; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Technology, Pharmaceutical; Thermogravimetry; Vibration; Water; Zalcitabine | 2015 |
Conjugates of phosphorylated zalcitabine and lamivudine with SiO
Topics: Anti-HIV Agents; Cell Line, Transformed; Cell Proliferation; Click Chemistry; HIV-1; Humans; Lamivudine; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Nanoparticles; Phosphorylation; Silicon Dioxide; Spectrometry, Mass, Electrospray Ionization; Zalcitabine | 2017 |